Antares Pharma, Inc. (ATRS) Income Statement Analysis

See more : Findit, Inc. (FDIT) Income Statement Analysis – Financial Results

Complete financial analysis of Antares Pharma, Inc. (ATRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Antares Pharma, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Antares Pharma, Inc. (ATRS)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.antarespharma.com

About Antares Pharma, Inc.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Revenue	183.98M	149.60M	123.86M	63.55M	54.52M	52.22M	45.66M	26.50M	20.62M	22.58M	16.46M	12.82M	8.31M	5.66M	7.86M	4.27M	2.22M	2.75M	3.79M	4.00M	3.50M	1.99M	3.48M	2.75M	3.72M	3.69M
Cost of Revenue	68.28M	63.10M	50.48M	31.07M	27.47M	28.82M	19.46M	11.24M	9.20M	9.52M	6.80M	4.27M	4.14M	2.02M	3.44M	1.56M	1.14M	1.37M	2.01M	2.57M	1.86M	1.65M	1.79M	1.85M	1.22M	1.14M
Gross Profit	115.70M	86.50M	73.39M	32.49M	27.05M	23.41M	26.20M	15.26M	11.42M	13.06M	9.66M	8.55M	4.17M	3.64M	4.41M	2.71M	1.09M	1.37M	1.78M	1.42M	1.64M	346.65K	1.70M	898.84K	2.50M	2.56M
Gross Profit Ratio	62.89%	57.82%	59.25%	51.12%	49.62%	44.82%	57.38%	57.60%	55.39%	57.83%	58.70%	66.66%	50.19%	64.32%	56.19%	63.55%	48.90%	50.02%	46.98%	35.60%	46.75%	17.39%	48.72%	32.67%	67.15%	69.22%
Research & Development	14.50M	10.12M	10.62M	12.33M	13.15M	21.13M	19.73M	18.64M	15.26M	14.92M	6.70M	8.80M	7.90M	7.87M	5.36M	3.78M	3.41M	3.55M	3.49M	3.65M	3.56M	1.22M	2.42M	3.52M	2.57M	2.58M
General & Administrative	0.00	62.76M	61.77M	36.76M	30.35M	26.39M	26.93M	31.74M	8.29M	7.20M	5.85M	4.73M	4.91M	6.35M	7.70M	7.21M	6.27M	6.20M	6.92M	6.03M	6.70M	1.97M	1.83M	2.43M	3.36M	1.40M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.71M	2.38M	1.55M	1.04M	1.05M	1.62M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	627.91K	1.06M	1.00M	0.00	1.02M
SG&A	73.86M	62.76M	61.77M	36.76M	30.35M	26.39M	26.93M	31.74M	17.01M	9.59M	7.40M	5.77M	5.96M	7.97M	7.70M	7.21M	6.27M	6.20M	6.92M	6.03M	6.70M	2.60M	2.89M	3.43M	3.36M	2.42M
Other Expenses	68.28M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00M	0.00	1.39M	0.00	0.00	0.00	0.00
Operating Expenses	156.64M	72.88M	72.40M	49.09M	43.50M	47.52M	46.66M	50.38M	32.27M	24.51M	14.10M	14.57M	13.86M	15.84M	13.06M	10.99M	9.68M	9.75M	10.41M	11.68M	10.26M	5.22M	5.31M	6.94M	5.94M	5.00M
Cost & Expenses	224.92M	135.98M	122.87M	80.16M	70.97M	76.34M	66.12M	61.61M	41.47M	34.03M	20.90M	18.85M	18.00M	17.86M	16.50M	12.55M	10.81M	11.12M	12.42M	14.26M	12.12M	6.87M	7.09M	8.80M	7.16M	6.14M
Interest Income	0.00	0.00	0.00	0.00	0.00	79.78K	60.47K	76.66K	111.58K	63.20K	55.59K	30.68K	27.27K	553.06K	0.00	353.24K	128.83K	0.00	16.54K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	3.79M	3.55M	2.68M	1.42M	0.00	0.00	0.00	0.00	0.00	887.00	4.46K	633.46K	1.02M	0.00	3.13K	576.00	0.00	920.13K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.90M	2.63M	2.56M	2.72M	2.10M	1.86M	1.57M	1.22M	558.28K	231.03K	168.17K	188.75K	226.38K	283.32K	2.78M	493.62K	513.26K	776.33K	894.30K	2.05M	560.63K	413.70K	461.34K	596.73K	326.07K	178.53K
EBITDA	66.17M	16.34M	4.08M	-1.12M	-13.22M	-22.38M	-18.91M	-33.90M	-20.25M	-11.20M	-4.22M	-5.90M	-9.43M	-11.39M	-5.80M	-7.60M	-7.98M	-7.57M	-31.00M	-9.55M	-8.94M	-4.47M	-3.24M	-5.17M	-2.65M	-2.06M
EBITDA Ratio	35.97%	10.92%	3.29%	-1.76%	-24.24%	-42.85%	-41.43%	-127.93%	-98.21%	-49.60%	-25.63%	-46.01%	-113.47%	-201.13%	-73.83%	-178.13%	-358.88%	-275.76%	-818.72%	-239.11%	-255.43%	-224.17%	-93.11%	-188.04%	-71.18%	-55.80%
Operating Income	62.27M	13.62M	992.00K	-4.10M	-16.45M	-24.12M	-20.46M	-35.11M	-20.85M	-11.45M	-4.44M	-6.03M	-9.69M	-12.20M	-8.65M	-8.28M	-8.59M	-8.37M	-8.63M	-10.26M	-9.57M	-4.87M	-3.61M	-6.05M	-3.44M	-2.45M
Operating Income Ratio	33.85%	9.10%	0.80%	-6.45%	-30.18%	-46.18%	-44.82%	-132.49%	-101.12%	-50.73%	-26.96%	-47.01%	-116.64%	-215.48%	-110.04%	-193.91%	-386.07%	-304.98%	-228.00%	-256.82%	-273.56%	-244.42%	-103.71%	-219.78%	-92.55%	-66.25%
Total Other Income/Expenses	0.00	-3.70M	-3.02M	-2.41M	-292.00K	-122.34K	-21.87K	-13.42K	43.54K	24.05K	-5.84K	-90.95K	9.08K	-23.87K	-33.03K	-173.12K	-37.04K	6.31K	-23.28M	-1.35M	73.46K	-9.97K	0.00	0.00	0.00	0.00
Income Before Tax	62.27M	9.92M	-2.03M	-6.52M	-16.74M	-24.24M	-20.48M	-35.13M	-20.81M	-11.43M	-4.44M	-6.12M	-9.68M	-12.22M	-8.68M	-8.45M	-8.63M	-8.37M	-31.91M	-11.61M	-9.50M	-4.88M	0.00	0.00	0.00	0.00
Income Before Tax Ratio	33.85%	6.63%	-1.64%	-10.25%	-30.71%	-46.41%	-44.86%	-132.55%	-100.91%	-50.62%	-26.99%	-47.72%	-116.53%	-215.91%	-110.46%	-197.97%	-387.74%	-304.75%	-842.77%	-290.50%	-271.46%	-244.92%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	15.98M	-46.28M	530.00K	261.00K	1.13M	100.00K	175.00K	25.00K	-300.00K	24.05K	-4.95K	-86.49K	642.54K	997.81K	-33.03K	-169.99K	-36.46K	6.31K	-22.36M	1.10K	2.03K	-9.97K	0.00	0.00	0.00	0.00
Net Income	46.29M	56.20M	-2.03M	-6.52M	-16.74M	-24.34M	-20.66M	-35.15M	-20.51M	-11.43M	-4.39M	-6.09M	-10.29M	-12.69M	-8.58M	-8.10M	-8.50M	-8.35M	-32.82M	-11.61M	-9.50M	-4.88M	-3.70M	-5.77M	-2.97M	-2.24M
Net Income Ratio	25.16%	37.57%	-1.64%	-10.25%	-30.71%	-46.61%	-45.25%	-132.64%	-99.46%	-50.62%	-26.66%	-47.52%	-123.82%	-224.18%	-109.19%	-189.76%	-381.97%	-304.03%	-866.63%	-290.53%	-271.52%	-244.92%	-106.36%	-209.73%	-79.95%	-60.64%
EPS	0.27	0.33	-0.01	-0.04	-0.11	-0.16	-0.14	-0.27	-0.16	-0.10	-0.05	-0.07	-0.14	-0.19	-0.14	-0.16	-0.20	-0.23	-2.17	-1.21	-1.12	-3.42	-2.60	-4.06	-2.12	-1.93
EPS Diluted	0.27	0.33	-0.01	-0.04	-0.11	-0.16	-0.14	-0.27	-0.16	-0.10	-0.05	-0.07	-0.14	-0.19	-0.14	-0.16	-0.20	-0.23	-2.17	-1.21	-1.12	-3.42	-2.60	-4.06	-2.12	-1.93
Weighted Avg Shares Out	170.16M	170.16M	202.70M	162.88M	156.05M	154.99M	146.59M	130.55M	126.90M	110.19M	96.99M	83.17M	73.49M	67.23M	59.60M	51.58M	41.46M	36.35M	15.09M	9.62M	8.49M	1.43M	1.42M	1.42M	1.40M	1.16M
Weighted Avg Shares Out (Dil)	170.16M	170.16M	202.70M	162.88M	156.05M	154.99M	146.59M	130.55M	126.90M	110.19M	96.99M	83.17M	73.49M	67.23M	59.60M	51.58M	41.46M	36.35M	15.09M	9.62M	8.49M	1.43M	1.42M	1.42M	1.40M	1.16M

QIC Global promotes Alexander Craggs to CEO at Antares - Reinsurance News

July 8, 2020reinsurancene.ws

QIC Global, the international specialty re/insurance arm of Qatar Insurance Group, has named Alexander Craggs as acting Chief Executive Officer (CEO) and

Antares Supports Quad-C Management’s PRISM Vision Group as It Acquires The Retina Group of Washington

July 6, 2020businesswire.com

Antares announced today that it served as joint lead arranger and is acting as administrative agent on $330 million in senior secured credit facilitie

‘Buck Moon’ Wanes As Bright Planets Peak: What You Can See In The Night Sky This Week

July 5, 2020forbes.com

The celestial highlights for the week ahead.

Unprecedented Astronomy: Atmosphere of the Red Supergiant Star Antares Revealed by Radio Telescopes

July 4, 2020scitechdaily.com

An international team of astronomers has created the most detailed map yet of the atmosphere of the red supergiant star Antares. The unprecedented sensitivity and resolution of both the Atacama Large Millimeter/submillimeter Array (ALMA) and the National Science Foundation’s Karl...

Comparing Antares Pharma (NASDAQ:ATRS) & STRATA Skin Sciences (NASDAQ:SSKN)

July 3, 2020thelincolnianonline.com

Antares Pharma (NASDAQ:ATRS) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and...